Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 19, 1999

View Archived Issues

Long-term E-4010 improves mortality in pulmonary hypertensive rats

ImmunoGen presents positive pharmacokinetic data for huC242-DM1/SB-408075

AltaRex reports new partnering plans for OvaRex MAb

Verteporfin prevents vision loss in AMD patients with predominantly classic CNV lesions

Genzyme General updates progress on development programs

Pharmos updates status of development programs

Selective inhibitors of alpha4 integrins designed at Celltech as cell adhesion modulators

Pharmacia & Upjohn presents new thiadiazoles for CMV infections

19-Nor-vitamin D3 compounds show promise in osteoporosis

Trisulfide immunostimulants and their use in arteriosclerosis, etc.

Preparation and use of compounds which elevate PDH activity claimed in recent patent literature

Bristol-Myers Squibb discloses novel melatonergic agents

Glaxo Wellcome's Advair Diskus NDA to be reviewed at late November advisory committee meeting

Cardioprotective agent JTV-519 may also prevent atrial fibrillation

Effects of darglitazone on body weight, food intake and MC4 receptors in obese Zucker rats

Therion Biologics and NCI initiate phase II trial of novel melanoma vaccines

Texas Biotechnology presents new ETA antagonists at ET-6

Dimethaid granted license for Pennsaid Topical Lotion in the U.K.

UL-TG-307: effects on insulin sensitivity, secretion and metabolic effects in type II diabetics

Teveten now available in the U.S.

EASD news: mechanisms of glucose-dependent insulinotropic action of JTT-608 elucidated

Texas Biotechnology announces new preclinical, clinical data and future plans for sitaxsentan

Zopolrestat: first report of reversal of preexisting renal hyperperfusion for ARI

New directions in pain research

DuPont granted patent rights to Duke's new antiestrogens

Collaboration on MC-4 receptor agonists signed by Pharmacopeia and Roche

Rebetol combination therapy launched in Italy for treatment of chronic HCV

Clinical trial of Proneuron's spinal cord cell therapy OK'd in U.S. and Israel

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...